GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MEX:BMRN) » Definitions » Capital Expenditure

Biomarin Pharmaceutical (MEX:BMRN) Capital Expenditure : MXN-1,583.45 Mil (TTM As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Biomarin Pharmaceutical Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Biomarin Pharmaceutical's cash flow for capital expenditures for the three months ended in Mar. 2025 was MXN-343 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was MXN-1,583.45 Mil.

Biomarin Pharmaceutical Capital Expenditure Historical Data

The historical data trend for Biomarin Pharmaceutical's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Capital Expenditure Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,735.53 -2,445.78 -2,564.50 -1,826.62 -2,031.72

Biomarin Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -566.00 -400.09 -416.96 -423.35 -343.04

Biomarin Pharmaceutical Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,583.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomarin Pharmaceutical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MEX:BMRN) » Definitions » Capital Expenditure
Comparable Companies
EXEL MRNA ASND INSM INCY RPRX CORT ROIV RVMD TECH VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
BMRN:USA 1BMRN:Italy 0HNC:UK BM8:Germany B1MR34:Brazil BMRN:Austria
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
Website
https://www.biomarin.com
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.